demonstrated that the co-administration of a MUC1-MBP vaccine with αPD1 antibodies in the B16-MUC1 melanoma model markedly improved anti-tumor efficacy compared to the vaccine alone, mainly by elevating CD8+T cell, Th1, and Tc1 activities, and diminishing the proportion of MDSCs in the tumor microenvironment (116). Here, CD8A is linked to neoplasm.